![]() |
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |

Tagged: abt, eu, abbott, drug regulations and approval, emea, ra, as, humira, jia, jra
Abbott (NYSE: ABT) has simultaneously submitted regulatory applications for its drug product HUMIRA® (adalimumab): a supplemental Biologics License Application (sBLA) with the USFDA seeking approval to market HUMIRA® (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® … Continue Reading »